These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16888434)

  • 21. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
    Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C
    Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
    Hay JW; Zhou ZY
    Haemophilia; 2010 Mar; 16(2):366-8; discussion 369-71. PubMed ID: 19811544
    [No Abstract]   [Full Text] [Related]  

  • 23. Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion.
    Morfini M; Messori A; Longo G
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S11-4. PubMed ID: 8735791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B.
    Martinowitz UP; Schulman S
    Acta Haematol; 1995; 94 Suppl 1():35-42. PubMed ID: 7571993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bypassing agent regimens and costs for prophylaxis in patients with inhibitors.
    Gringeri A
    Haemophilia; 2009 Nov; 15(6):1336-7. PubMed ID: 19558488
    [No Abstract]   [Full Text] [Related]  

  • 26. The pharmacokinetics of clotting factor therapy.
    Berntorp E; Björkman S
    Haemophilia; 2003 Jul; 9(4):353-9. PubMed ID: 12828668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitor economics.
    Teitel J
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S14-7. PubMed ID: 16690371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The administration of factor VIII concentrates to hemophiliacs by continuous perfusion pump].
    Rodríguez Bueno S; Montoro Ronsano JB; Martínez Sánchez B; Altisent Roca C; Tusell Puigvert JM
    Med Clin (Barc); 1991 Mar; 96(10):364-6. PubMed ID: 1904520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis and treatment of congenital hemophilia with inhibitors a Latin American perspective.
    Pérez Bianco R; Ozelo MC; Villaça PR; Solano MH; Jimenez Cruze G; Martinez Murillo C; Garcia Chavez J; Mendoza S; Rodriguez Grecco I; Ruiz-Saez A
    Medicina (B Aires); 2008; 68(3):227-42. PubMed ID: 18689157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of high-purity concentrates in haemophiliac patients undergoing surgery by continuous infusion.
    Tagariello G; Davoli PG; Gajo GB; De Biasi E; Risato R; Baggio R; Traldi A
    Haemophilia; 1999 Nov; 5(6):426-30. PubMed ID: 10583530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors.
    Gomperts ED; Astermark J; Gringeri A; Teitel J
    Blood Rev; 2008 Feb; 22 Suppl 1():S1-11. PubMed ID: 18485996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylaxis in haemophilia with inhibitors: update from international experience.
    Carcao M; Lambert T
    Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of continuous infusion versus bolus injection of factor concentrates for blood management after total knee arthroplasty in patients with hemophilia.
    Park YS; Shin WJ; Kim KI
    BMC Musculoskelet Disord; 2017 Aug; 18(1):356. PubMed ID: 28830476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.
    Schaub RG
    Biochem Pharmacol; 2011 Jul; 82(2):91-8. PubMed ID: 21453683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infection risk and stability of a continuous 8-h 250 mL rFVIII infusion.
    Lambing A; Kuriakose P; Mueller LM
    Haemophilia; 2014 Mar; 20(2):212-8. PubMed ID: 24251950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
    Franchini M; Coppola A; Tagliaferri A; Lippi G
    Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose and response in haemophilia--optimization of factor replacement therapy.
    Srivastava A
    Br J Haematol; 2004 Oct; 127(1):12-25. PubMed ID: 15384973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient.
    Rosenfeld SB; Watkinson KK; Thompson BH; Macfarlane DE; Lentz SR
    Thromb Haemost; 2002 May; 87(5):925-6. PubMed ID: 12038803
    [No Abstract]   [Full Text] [Related]  

  • 40. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
    Négrier C; Shapiro A; Berntorp E; Pabinger I; Tarantino M; Retzios A; Schroth P; Ewenstein B
    Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.